Germany first in EU to get Novartis’ SMA gene therapy, costing almost 2 million euros

24 June 2020 - Novartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal ...

Read more →

Report calls for European funding reform for gene therapies

8 July 2019 - New payment models, dedicated investment, and better health technology assessment are among a raft of changes ...

Read more →

Europe responding to gene therapy challenge, but picture remains fragmented

20 May 2019 - Germany, Italy and England using outcomes-based deals. ...

Read more →